abstract |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Z is (a), (b) or (c); W1 is S, O or N-R; V1 is N or C; W 2 is N or C; V 2 is S, O or N-R; a is 0 or 1, b is 0 or 1, m is 0, 1 or 2, s is 1 or 2; t is 1, 2 or 3; X = Y is C = N, N = C or C = C; R is hydrogen or alkyl; R1 and R5 are hydrogen, (C = O) aObalkyl, (C = O) aObaryl, (C = O) aObalkenyl, (C = O) aObalkynyl, CO2H, halogen, hydroxy, Ob- perfluoroalkyl, (C = O) aNR7R8, CN, (C = O) aOb-cycloalkyl, (C = O) aOb-heterocyclyl, R2 and R3 are hydrogen, (C = O) alkyl, (C = O) Oa-aryl, alkyl, SO2Ra or aryl; R4 is (C = O) aOb-alkyl, (C = O) aOb-aryl, (C = O) aObalkenyl, (C = O) aOb-alkynyl, CO2H, halogen, hydroxy, Ob-perfluoroalkyl -, (C = O) a NR7R8, CN, (C = O) aOb-cycloalkyl, (C = O) aOb-heterocyclyl, R7 and R8 are hydrogen, (C = O) Obalkyl -, (C = O) ) Obcycloalkyl, (C = O) Ob-aryl, (C = O) Ob-heterocyclyl, alkyl, aryl, alkenyl, alkynyl, heterocyclyl, cycloalkyl, SO 2 R a, or (C = O) NR b 2 or R7 and R8 together with the nitrogen atom form a monocyclic or bicyclic heterocycle; Ra is alkyl, cycloalkyl, aryl or heterocyclyl; and R b is hydrogen, alkyl, aryl, heterocyclyl, cycloalkyl, (C = O) O-alkyl, (C = O) -alkyl, or S (O) 2 R a. The invention also relates to pharmaceutical compositions comprising compounds of general formula (I). Compounds of the invention include angiogenesis, cancer, tumor growth, atherosclerosis, age-related pigment degeneration, diabetic retinopathy, inflammatory diseases, and the like. can be used. SHE |